Due to scheduled maintenance work on our servers, there may be short service disruptions on this website between 11:00 and 12:00 CEST on March 28th.
Biologics and Biosimilars
A section of Pharmaceutics (ISSN 1999-4923).
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Biotechnology Applications and Innovative Approaches for Cancer Prevention and Treatment (BIO-APP) (Deadline: 31 March 2026)
- Peptide Polymer Delivery Systems for Antibacterial and Immunomodulatory Applications (Deadline: 31 March 2026)
- Medical Applications of Biologic Drugs (Deadline: 20 April 2026)
- Therapeutic Advances in Chronic Diseases: Innovation and Drug Repurposing (Deadline: 30 April 2026)
- Impacts of the Kallikrein–Kinin System in Cancer and Its Treatment: A Focus on Drug Delivery and Formulations (Deadline: 31 May 2026)
- Antibody–Drug Conjugates Therapeutics (Deadline: 31 May 2026)
- Next-Generation Delivery Systems for Peptides, Proteins, and Nucleic Acids (Deadline: 31 May 2026)
- Recent Advances in Antibody–Drug Conjugates for Cancer Therapy (Deadline: 30 June 2026)
- Modern Formulation and Applications of Probiotics (Deadline: 20 August 2026)
- Bioactive Molecules for Targeted Cancer Therapy and Delivery Innovations (Deadline: 13 September 2026)
- Biosimilars in Oncology: Applications in Pharmaceutics and Pharmaceuticals (Deadline: 30 November 2026)
